Strategic partnerships Mirimus has a track record of collaborating with major biopharma and academic institutions (Biogen, St. John’s University, Eckerd College, Yale, Pingry School) for high-volume testing and drug discovery support, indicating a strong sales path for diagnostic platforms, surveillance testing services, and RNAi/CRISPR model libraries.

RNAi and CRISPR advantage The company specializes in RNAi and CRISPR Cas9 models for drug discovery and target validation, presenting opportunities to upsell custom model development services, companion diagnostics, and collaborative research programs with biotech and pharma partners.

Global health focus Mirimus emphasizes global health equity and scalable, affordable diagnostics, suggesting value propositions around cost-effective testing platforms, mass-screening programs, and deployment-ready diagnostic tools for emerging markets and large institutions.

Analytics and cloud With a tech stack including AWS, HubSpot Analytics, and Webflow, there is potential to offer data integration, analytics, and workflow automation services for customers needing end-to-end lab data management, reporting dashboards, and scalable cloud-based solutions.

Growth through services Revenue in the mid single to mid double digits and a history of high-volume PCR testing collaborations indicate an opportunity to cross-sell additional services such as expanded surveillance testing, validation studies, and rapid model-based assay development to existing customers and new research institutions.